Overview

Intravitreal Celecoxib for Chronic Uveitis

Status:
Terminated
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
Intraocular delivery of celecoxib will be an effective means to treat inflammation and macular edema and prevent structural complications and vision loss in patients with chronic inflammation or macular edema who are unable to tolerate corticosteroids due to their side effects.
Phase:
Phase 1
Details
Lead Sponsor:
Vanderbilt University
Collaborator:
Pfizer
Treatments:
Celecoxib